Dendreon Pharmaceuticals LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Apr 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 30, 2027The maintenance fee for Gene expression markers for predicting overall survival in subjects treated with sipuleucel-T (US 11,970,743) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,597,894 | Compositions and Methods Employing Alternative Reading Frame Polypeptides for the Treatment of Cancer and Infectious Disease In force · High confidence | In force | High confidence | |
| US 7,972,602 | Promiscuous HER-2/NEU CD4 T Cell Epitopes In force · High confidence | In force | High confidence | |
| US 8,263,757 | Promiscuous HER-2/Neu CD4 T cell epitopes In force · From the USPTO record | In force | From the USPTO record | |
| US 8,647,865 | Promiscuous Pap CD4 T Cell Epitopes In force · High confidence | In force | High confidence | |
| US 8,153,120 | Methods for Inducing a Natural Killer (NK) Cell-Mediated Immune Response and for Increasing NK Cell Activity In force · High confidence | In force | High confidence | |
| US 8,361,479 | Promiscuous Pap CD4 T Cell Epitopes In force · High confidence | In force | High confidence | |
| US 10,261,091 | Humoral Immune Response Against Tumor Antigens After Treatment with a Cancer Antigen Specific Active Immunotherapy and Its Association with Improved Clinical Outcome In force · High confidence | In force | High confidence | |
| US 11,970,743 | Gene expression markers for predicting overall survival in subjects treated with sipuleucel-T In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 8: 36 lapsed for an unpaid fee · 71 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned